Outcomes of Clareon PanOptix in Patients With Prior Myopic Refractive Surgery

Description

This study is a Single center, single arm, prospective, observational study of clinical outcomes following bilateral cataract surgery and Clareon PanOptix implantation. Subjects will be assessed preoperatively, and at 1 and 3 months postoperatively. Clinical evaluations will include administration of the QUVID and IOLSAT questionnaires, manifest refraction, topography, as well as measurement of visual acuities at distance, intermediate, and near.

Conditions

Cataract

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is a Single center, single arm, prospective, observational study of clinical outcomes following bilateral cataract surgery and Clareon PanOptix implantation. Subjects will be assessed preoperatively, and at 1 and 3 months postoperatively. Clinical evaluations will include administration of the QUVID and IOLSAT questionnaires, manifest refraction, topography, as well as measurement of visual acuities at distance, intermediate, and near.

Visual and Refractive Outcomes of the Clareon PanOptix IOL in Patients With Prior Myopic Refractive Surgery

Outcomes of Clareon PanOptix in Patients With Prior Myopic Refractive Surgery

Condition
Cataract
Intervention / Treatment

-

Contacts and Locations

Albuquerque

Juliette Eye Institute Research Center, Albuquerque, New Mexico, United States, 87113

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults (45 years or older) who have confirmed age-related cataracts and are eligible for bilateral cataract surgery.
  • * Prior binocular myopic photorefractive keratectomy (PRK) or myopic LASIK.
  • * Patients who have regular corneal astigmatism less than or equal to 0.6 D and are candidates for the PanOptix spherical IOL.
  • * Patients who have regular corneal astigmatism and are candidates for PanOptix toric IOL T3
  • * Postoperative visual potential of monocular 20/25 or better, in the surgeon's judgement.
  • * Any ocular comorbidity that might hamper postoperative visual acuity:
  • * Corneal abnormality including corneal dystrophy, irregularity, and degeneration.
  • * Moderate or severe dry eyes that can't be relieved after treatment.
  • * History of or current anterior and posterior inflammation of any etiology.
  • * Retinal pathology such as AMD, diabetic retinopathy, vein occlusion, etc.
  • * Glaucoma of any kind.
  • * Pregnancy or lactation.
  • * Any ocular surgery other than corneal myopic refractive surgery (LASIK and PRK).
  • * Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease, unable to fixate)
  • * Apple Kappa/chord mu ≥ 0.6.
  • * Higher order corneal aberrations at pupil diameter of 4mm: \> 0.6 total RMS, \> 0.3 coma, \> 0.3 trefoil (to exclude irregular corneas)
  • * Any patient requiring a limbal relaxing incision.

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Juliette Eye Institute Research Center,

Robert Melendez, MD, MBA, PRINCIPAL_INVESTIGATOR, Juliette Eye Institute Research Center

Study Record Dates

2025-09-01